Skip to content

Does Immunotherapy Have a Role in the Management of Endometriosis?

Does Immunotherapy Have a Role in the Management of Endometriosis?

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03464799
Enrollment
40
Registered
2018-03-14
Start date
2018-09-30
Completion date
2018-12-31
Last updated
2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

Pathological specimens of 40 women that had been operated for endometriosis will be included in this study. These tissues will be stained with a marker named as PDL-1 in pathological examination. programmed cell death (PD-1) is expressed on T cells. The immunotherapies in which antibodies against these PD-1 and its ligands (PDL-1) have been used are accepted as very effective in the treatment of many cancers. If these ligands can be shown in the endometriosis, it will be an important step for the treatment of endometriosis.

Detailed description

40 women who had been operated for endometriosis between 2013 and 2014 will be included in this study. Pathological specimens will be stained with an immunohistochemical marker named as PDL-1. programmed cell death (PD-1) is a protein containing 288 aminoacids and expressed on T cells. It was shown on apoptotic cells in earlier times, but then it has been understood that its physiologic role is not cell death. The upregulation of PD-1 is a result of the activation of T cells and it is necessary for the termination of immune response. PD-L1 is a ligand for PD-1. The immunotherapies in which antibodies against these PD-1 and its ligands (especially PDL-1) provides significant improvements in many cancers such as melanoma. Evidence about the role of these ligands in endometriosis will be an important step in its management.

Interventions

immunohistochemical staining

Sponsors

Kanuni Sultan Suleyman Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* patients operated for endometriosis between 2013 and 2014 * pathological examinations proving the diagnosis of endometriosis

Exclusion criteria

* patients operated for cysts other than endometriosis

Design outcomes

Primary

MeasureTime frameDescription
immunohistochemical staining6 monthsimmunohistochemical staining with PD-L1

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026